

We are advancing a deep and broad portfolio of product candidates derived from our four drug classes focused on the treatment of cancer, infectious diseases and other indications of unmet patient need:

Oncology

Drug class	Platform	Product candidate	Indication (target)	Phase 1	Phase 1/2	Phase 2	Phase 3	Rights/Collaborator
mRNA	FixVac	BNT111	Advanced, R/R melanoma	█	█	█		Fully owned ¹
		BNT112	Metastatic/localized prostate cancer	█	█			
		BNT113	Metastatic/ R/R HPV16+ head and neck cancer	█	█	█		
		BNT116	1L metastatic NSCLC	█	█	█		
	iNeST	BNT122 (Autogene cevumeran)	1L advanced melanoma	█	█	█		Genentech ² (global 50:50 profit/loss share)
			Adjuvant colorectal cancer	█	█	█		
	Intratumoral immunotherapy	BNT131 (SAR441000)	Multiple solid tumors (IL-12sc, IL-15 sushi, GM-CSF, IFN α) ³	█				Sanofi (global profit/loss share)
	RiboMabs	BNT142	Multiple solid tumors (CD3xCLDN6)	█	█			Fully owned
	RiboCytokines	BNT151	Multiple solid tumors (IL-2 variant)	█	█			Fully owned
		BNT152 + BNT153	Multiple solid tumors (IL-7, IL-2)	█				
Cell therapies	CAR T cells + CARVac	BNT211	Multiple solid tumors (CLDN6)	█	█			Fully owned
	Neoantigen-based T cells	BNT221	Refractory metastatic melanoma	█				Fully owned
Protein-based therapeutics	Next-generation immune checkpoint modulators	BNT311 (GEN1046)	aPD(L)1-R/R metastatic NSCLC (PD-L1x4-1BB)	█	█	█		Genmab (global 50:50 profit/loss share)
		BNT312 (GEN1042)	Multiple solid tumors (PD-L1x4-1BB)	█	█			
		BNT313 (GEN1053)	Multiple solid tumors (CD40x4-1BB) ⁴	█	█			
		BNT322 (GEN1056)	Multiple solid tumors	█				
		BNT316 (ONC-392)	aPD(L)1-R/R metastatic NSCLC (CTLA-4)	█	█	█		
	BNT316 (ONC-392)	Platinum-resistant ovarian cancer (CTLA-4)	█	█	█			
	Targeted cancer antibodies	BNT321	Pancreatic cancer (sLea)	█				Fully owned
		Antibody-drug conjugates	BNT323 (DB-1303)	Multiple solid tumors (HER2)	█	█		
	BNT325 (DB-1305)		Multiple solid tumors	█	█			
	SMIM ⁵	Toll-like receptor binding	BNT411	Multiple solid tumors (TLR7)	█	█		

Infectious Diseases

Drug class	Product candidate	Indication	Phase 1	Phase 1/2	Phase 2	Phase 3	Commercial	Rights/Collaborator
mRNA	COMIRNATY (BNT162b2)	COVID-19	█	█	█	█	█	Fosun Pharma (Mainland China, Hong Kong SAR, Macau SAR, Taiwan region) Pfizer (rest of the world) ⁶
	BNT162b4 (T-cell enhancing)		█					
	BNT162b5 (Enhanced spike antigen)		█	█	█			
	BNT162b2+BNT161 ⁷	COVID-19 – Influenza combination	█					Partnered with Pfizer globally
	BNT161	Influenza	█	█	█			Exclusive license to Pfizer
	BNT163	HSV-2	█					Collaboration with University of Pennsylvania
	BNT164 ⁸	Tuberculosis	█					Collaboration with Bill & Melinda Gates Foundation
	BNT165	Malaria	█					Fully owned
	BNT167	Shingles	█	█				Partnered with Pfizer globally

¹ FixVac platform is fully owned by BioNTech. The BNT111 and BNT116 Phase 2 trials are jointly conducted with Regeneron as part of a cost-sharing strategic collaboration.

² A member of the Roche group.

³ Study status active; recruitment stopped; program discontinued.

⁴ Two Phase 1/2 clinical trials in patients with solid tumors are ongoing in combination with ICI+/- chemotherapy.

⁵ Small Molecule Immunomodulators.

⁶ BioNTech holds the commercialization license in Türkiye and Germany as part of the collaboration with Pfizer.

⁷ The COVID-19-Influenza combination is a Phase 1 trial in partnership with Pfizer. Further development is subject to reaching agreement.

⁸ BioNTech holds worldwide distribution rights except developing countries where Bill & Melinda Gates Foundation holds distribution rights.